Two-year results from the recently-completed HARBOR trial showed that some patients with wet AMD fare as well from Lucentis (ranibizumab) injections on an as-needed basis compared to a monthly basis. The original Lucentis trial recommended monthly dosing until the eye stabilized. The follow-up study, however, found that 93% of patients responded well with an average treatment interval of 9.9 weeks after the first three loading doses. This indicates that Lucentis treatment for wet AMD could become less burdensome for the majority of patients.
Source: Healio.com
